Background
Liraglutide, 97% similar to native human GLP-1, differs primarily by substituting arginine for lysine at position 34 and involves attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer at the remaining lysine residue at position 26.• The physiology of glucagon-like peptide 1., PMID:17928588• Glucagon-like peptide-1 receptor: mechanisms and advances in therapy., PMID:39289339• The structure and function of the glucagon-like peptide-1 receptor and its ligands., PMID:21950636• Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist., PMID:33177239• Glucagon-like peptide-1 receptor., PMID:39626623• Prognostic impact of glucagon-like peptide-1 receptor (GLP1R) expression on cancer survival and its implications for GLP-1R agonist therapy: an integrative analysis across multiple tumor types., PMID:39777709• Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials., PMID:28244632• Glucagon-like-peptide 1 receptor agonism and attempted suicide: A Mendelian randomisation study to assess a potential causal association., PMID:38778795• Glucagon-Like Peptide-1 Receptor Agonism and Suicide Risk: Evidence From Mendelian Randomization., PMID:38879463• GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis., PMID:39735270